False-positive results of Aspergillus enzymelinked immunosorbent assay in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation
Serological assays are helpful in the diagnosis of invasive aspergillosis in febrile neutropenic patients. Most efforts have been concentrated on the detection of circulating galactomannan (GM) antigen, a major cell wall component of Aspergillus. Recently, a commercial test has been developed using a double direct sandwich enzyme-linked immunosorbent assay (EIA) (Platelia Aspergillus; BioRad, Marnes La Coquette, France). 1 The test has a sensitivity of 67-100% and a specificity of 81-99% when performed with serum samples drawn from neutropenic patients receiving cytotoxic chemotherapy for hematological malignancy.
2-5 Higher antigen levels are useful in predicting disseminated disease, and the course of the antigenemia is correlated with clinical outcome. 6 Because of its high specificity and sensitivity, GM EIA is widely applied in the diagnosis and management of invasive aspergillosis. We describe a patient who gave positive results on the GM EIA, but had no other signs of invasive aspergillosis. These samples were regarded as false-positives. This problem, although seldom reported in the medical literature, might be familiar to those who have been involved in the development and evaluation of the diagnostic tests for invasive aspergillosis after BMT. However, the mechanism of this false-positive result remains to be clarified. A detailed description of this patient's clinical course will provide important information on possible mechanisms of falsepositives of GM EIA. To our knowledge, this is the first report on an association between false-positives of GM EIA and chronic GVHD.
A 39-year-old woman with acute myeloid leukemia in remission underwent BMT from an HLA-identical unrelated donor in March 2000. Conditioning consisted of busulfan and cyclophosphamide. GVHD prophylaxis was a combination of cyclosporine and short-term methotrexate. 200 mg of fluconazole were given as fungal prophylaxis. GM EIA had been tested four times up to day 100 after BMT, and all of these tests were negative. Her clinical course had been uneventful until August 2000, when chronic graft-versus-host disease involving skin, oral mucosa and gut developed. Serological abnormalities including elevated levels of IgM paraprotein, circulating immune complexes and several types of auto-reactive antibodies were also detected. She was afebrile, and had no respiratory signs. We initiated 1 mg/kg of predonisone on day 225. Later, we were very surprised to be informed of the results of the GM EIA. The OD ratio was more than 5.0 (normal value less than 1.5). We thoroughly examined her respiratory system. However, the findings of repeated chest CT scans were normal. Plasma levels of beta D-glucan (BDG) were not elevated. BDG is one of the major structural cell-wall components of most fungi, and determination of its plasma level is a useful guide for the diagnosis of invasive mycosis. Its sensitivity and specificity are reported to be 90% and 100%, respectively. 7 AspergillusBone Marrow Transplantation specific DNA was not identified from the blood using polymerase chain reaction. 8 The positive sample was therefore diagnosed as a false-positive. Antigen detection assays for Candida or Cryptococcus were not performed, because there was a possibility that these tests might have shown similar false-positive results. We did not carry out protein electrophoresis during the period of chronic GVHD, since there might have been protein or antibody reacting with anti-GM antibodies. The GVHD lesions responded to the immunosuppressive treatment. The oral lesions and diarrhea had disappeared by day 378. The skin lesions resolved with formation of mild hyperkeratosis and hyperpigmentation. With the improvement in chronic GVHD the OD ratio of GM EIA decreased, and became normal by day 322. We did not administer anti-Aspergillus treatment during her clinical courses. The association between severity of GVHD and OD ratio of EIA is shown in Figure 1 .
Definite conclusions on the exact mechanism of falsepositives of EIA cannot be drawn from this case report, but we can suggest some possibilities. The first is the presence of occult infection or transient Aspergillus antigenemia. False-positive results of GM EIA have been reported to occur in BMT recipients, 9 neutropenic patients 10 and premature neonates. 11 Because these patients have dysfunction of the intestinal or bronchial mucosal barrier, fecal or bronchial GM antigens may reach the circulation, thus leading to diagnostically false-positive antigenemia. However, it is to be noted that the patient received high-dose corticosteroid for the treatment of GVHD, that she had never received anti-Aspergillus treatment throughout her clinical course, and that most false-positives with the antigen detection test develop immediately after BMT or cytotoxic chemotherapy.
2,10 These findings do not support the possibility that occult invasive aspergillosis might have existed and been cleared spontaneously in this patient.
The second possibility is that some antigens reacting with GM EIA might have been present in the blood from this patient. GM EIA is reported to react with metabolites of cyclophosphamide 12 and some fungi including Penicillium and Paecliomyces. 13 This patient had not received cyclophosphamide when the GM EIA became positive, and there were no findings suggesting the presence of occult infection by these organisms. However, it is interesting that there was a marked correlation between the severity of chronic GVHD and results of GM EIA, and that several types of serological abnormalities were detected in this patient. The false-positives of GM EIA were closely associated with the presence of the abnormalities associated with chronic GVHD. Chronic GVHD sometimes manifests as autoimmune disorders, and serological abnormalities are common findings in chronic GVHD. 14 We suggest that the paraproteins or auto-reactive antibodies might have reacted with anti-GM antibodies.
BMT recipients are at high-risk of invasive aspergillosis, and GVHD and use of corticosteroids particularly increase the risk. Because GM EIA does not require invasive procedures, it is useful for diagnosing invasive aspergillosis after BMT. However, we should recognize that GM EIA could give false-positive results in patients with chronic GVHD. 
Rhizopus presenting as an endobronchial obstruction following bone marrow transplant
The Zygomycetes are a group of fungi found commonly in the soil and in decaying organic matter. Family members that infect humans include Mucor, Rhizopus, Absidia, and Cunninghamella species.
1,2 These spore-forming saprophytes can infect humans by inhalation of aerosolized spores. Although rare cases of zygomycete infection have been reported in immunocompetent subjects, the overwhelming majority occur in immunocompromised patients.
We report a case of an endobronchial obstructing lesion due to Rhizopus that proved fatal in a patient who had recently undergone umbilical cord blood transplant.
A 44-year-old man was admitted to the hospital to undergo umbilical cord blood transplant. Eight months prior to transplant he presented with pancytopenia and was diagnosed with M4 AML. His induction regimen included Ara-C and indarubicin. His course was complicated by vancomycin-resistant enterococcal bacteremia, which was treated with quinupristin/dalfopristin. A subsequent bone marrow aspirate demonstrated persistent blasts and further attempts at re-induction chemotherapy failed. The patient had no matching siblings and was deemed not to be a candi-
